How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales

被引:11
作者
Cocks, Kim [1 ,2 ]
Buchanan, Jacqueline [3 ]
机构
[1] KCStats Consultancy, Leeds, W Yorkshire, England
[2] Adelphi Values, Bollington, Cheshire, England
[3] Amgen Ltd, San Francisco, CA USA
关键词
Meaningful change; Responder definition; State change; EORTC QLQ-C30; QUALITY-OF-LIFE; NATIONAL-CANCER-INSTITUTE; CLINICAL-TRIALS; THERAPY;
D O I
10.1007/s11136-022-03181-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose The recommended method for establishing a meaningful threshold for individual changes in patient-reported outcome (PRO) scores over time uses an anchor-based method. The patients assess their perceived level of change and this is used to define a threshold on the PRO score which may be considered meaningful to the patient. In practice, such an anchor may not be available. In the absence of alternative information often the meaningful change threshold for assessing between-group differences, the minimally important difference, is used to define meaningful change at the individual level too. This paper will highlight the issues with this, especially where the underlying measurement scale is not continuous. Methods Using the EORTC QLQ-C30 as an example, plausible score increments ("state changes") are calculated for each subscale highlighting why commonly used thresholds may be misleading, including leading to sensitivity analyses that are inadvertently testing the same underlying threshold. Results The minimal possible individual score change varies across subscales; 6.7 for Physical Functioning, 8.3 for Global Health Scale and Emotional Functioning, 11.1 for fatigue, 16.7 for role functioning, cognitive functioning, social functioning, nausea and vomiting, pain and 33.3 for single items. Conclusions The determination of meaningful change for an individual patient requires input from the patients but being mindful of the underlying scale ensures that these thresholds are also guided by what is a plausible change for patients to achieve on the scale.
引用
收藏
页码:1247 / 1253
页数:7
相关论文
共 19 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   Sequential FOLFIRI.3+Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial [J].
Anota, Amelie ;
Mouillet, Guillaume ;
Trouilloud, Isabelle ;
Dupont-Gossart, Anne-Claire ;
Artru, Pascal ;
Lecomte, Thierry ;
Zaanan, Aziz ;
Gauthier, Melanie ;
Fein, Francine ;
Dubreuil, Olivier ;
Paget-Bailly, Sophie ;
Taieb, Julien ;
Bonnetain, Franck .
PLOS ONE, 2015, 10 (05)
[3]   Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? [J].
Anota, Amelie ;
Hamidou, Zeinab ;
Paget-Bailly, Sophie ;
Chibaudel, Benoist ;
Bascoul-Mollevi, Caroline ;
Auquier, Pascal ;
Westeel, Virginie ;
Fiteni, Frederic ;
Borg, Christophe ;
Bonnetain, Franck .
QUALITY OF LIFE RESEARCH, 2015, 24 (01) :5-18
[4]   Smallest real difference, a link between reproducibility and responsiveness [J].
Beckerman, H ;
Roebroeck, ME ;
Lankhorst, GJ ;
Becher, JG ;
Bezemer, PD ;
Verbeek, ALM .
QUALITY OF LIFE RESEARCH, 2001, 10 (07) :571-578
[5]   Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma [J].
Bonnetain, Franck ;
Dahan, Laetitia ;
Maillard, Emilie ;
Ychou, Marc ;
Mitry, Emmanuel ;
Hammel, Pascal ;
Legoux, Jean-Louis ;
Rougier, Philippe ;
Bedenne, Laurent ;
Seitz, Jean-Francois .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (15) :2753-2762
[6]   Lessons learned in the assessment of health-related quality of life: Selected examples from the national cancer institute of Canada clinical trials group [J].
Brundage, Michael ;
Osoba, David ;
Bezjak, Andrea ;
Tu, Dongsheng ;
Palmer, Michael ;
Pater, Joseph .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (32) :5078-5081
[7]   Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [J].
Cocks, Kim ;
King, Madeleine T. ;
Velikova, Galina ;
St-James, Marrissa Martyn ;
Fayers, Peter M. ;
Brown, Julia M. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :89-96
[8]   Health-related quality of life in patients with advanced prostate cancer undergoing treatment with TRIPTOrelin Pamoate SIX month formulation: Results of the non-interventional TRIPTOSIX study. [J].
Eisenhardt, Andreas ;
Schneider, Tim ;
Scheithe, Karl ;
Colling, Christiane ;
Heidenreich, Axel .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
[9]  
Fayers P., 2001, The EORTC QLQC30 Scoring Manual, 3rd ed, V3rd ed.
[10]   Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy [J].
Harrison, Claire N. ;
Mesa, Ruben A. ;
Kiladjian, Jean-Jacques ;
Al-Ali, Haifa-Kathrin ;
Gisslinger, Heinz ;
Knoops, Laurent ;
Squier, Margaret ;
Sirulnik, Andres ;
Mendelson, Estella ;
Zhou, Xiaolei ;
Copley-Merriman, Catherine ;
Hunter, Deborah S. ;
Levy, Richard S. ;
Cervantes, Francisco ;
Passamonti, Francesco ;
Barbui, Tiziano ;
Barosi, Giovanni ;
Vannucchi, Alessandro M. .
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (02) :229-239